| Anti-TNFs seem to be the most effective agents in preventing and treating postoperative recurrence in Crohn’s disease. These agents remain an effective option in patients with anti-TNF failure before surgery. |
| Vedolizumab seems to be quite effective in the prevention of postoperative recurrence. |
| Ustekinumab is probably also effective in the postoperative setting, although the comparative efficacy with anti-TNFs or vedolizumab is still unclear. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.